33182 Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: Results from the ALLEGRO phase 2b/3, randomized, double-blind, placebo-controlled trial

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2022
This article has no abstract
Epistemonikos ID: 8eb3f5969bdaec3ea168454d6670cace144e5027
First added on: Feb 15, 2025